Biotech Values

[mr_o]

Ron, CELG has a growth rate of 25% through 2017. It's P/E is pricey right now but that will change as Abraxane, Pomylast, Apremilast, and Rev in maintnance and EU all ramp up. The CELG story is as strong as ever. I too thought it was pricey at $100, only to buy in at 130 to 150. For a wealth of information visit the investor village CELG board. Good Luck.